Literature DB >> 8948338

A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.

A B Karim1, B Maat, R Hatlevoll, J Menten, E H Rutten, D G Thomas, F Mascarenhas, J C Horiot, L M Parvinen, M van Reijn, J J Jager, M G Fabrini, A M van Alphen, H P Hamers, L Gaspar, E Noordman, M Pierart, M van Glabbeke.   

Abstract

PURPOSE: Cerebral low-grade gliomas (LGG) in adults are mostly composed of astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas. There is at present no consensus in the policy of treatment of these tumors. We sought to determine the efficacy of radiotherapy and the presence of a dose-response relationship for these tumors in two multicentric randomized trials conducted by the European Organization for Research and Treatment of Cancer (EORTC). The dose-response study is the subject of this article. METHODS AND MATERIALS: For the dose-response trial, 379 adult patients with cerebral LGGs were randomized centrally at the EORTC Data Center to receive irradiation postoperatively (or postbiopsy) with either 45 Gy in 5 weeks or 59.4 Gy in 6.6 weeks with quality-controlled radiation therapy. All known parameters with possible influences on prognosis were prospectively recorded. Conventional treatment techniques were recommended.
RESULTS: With 343 (91%) eligible and evaluable patients followed up for at least 50 months with a median of 74 months, there is no significant difference in terms of survival (58% for the low-dose arm and 59% for the high-dose arm) or the progression free survival (47% and 50%) between the two arms of the trial. However, this prospective trial has revealed some important facets about the prognostic parameters: The T of the TNM classifications as proposed in the protocol appears to be one of the most important prognostic factors (p < 0.0001) on multivariate analysis. Other prognostic factors, most of which are known, have now been quantified and confirmed in this prospective study.
CONCLUSION: The EORTC trial 22844 has not revealed the presence of radiotherapeutic dose-response for patients with LGG for the two dose levels investigated with this conventional setup, but objective prognostic parameters are recognized. The tumor size or T parameter as used in this study appears to be a very important factor.

Entities:  

Mesh:

Year:  1996        PMID: 8948338     DOI: 10.1016/s0360-3016(96)00352-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  147 in total

Review 1.  Radiation therapy for incompletely resected supratentorial low-grade glioma in adults.

Authors:  B Jeremic; M Bamberg
Journal:  J Neurooncol       Date:  2001-11       Impact factor: 4.130

2.  The dilemma of low grade glioma.

Authors:  I R Whittle
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

3.  Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas.

Authors:  Johan Pallud; Jean-François Llitjos; Frédéric Dhermain; Pascale Varlet; Edouard Dezamis; Bertrand Devaux; Raphaëlle Souillard-Scémama; Nader Sanai; Maria Koziak; Philippe Page; Michel Schlienger; Catherine Daumas-Duport; Jean-François Meder; Catherine Oppenheim; François-Xavier Roux
Journal:  Neuro Oncol       Date:  2012-03-13       Impact factor: 12.300

4.  Relative survival of patients with supratentorial low-grade gliomas.

Authors:  Nicolas R Smoll; Oliver P Gautschi; Bawarjan Schatlo; Karl Schaller; Damien C Weber
Journal:  Neuro Oncol       Date:  2012-07-06       Impact factor: 12.300

5.  Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas.

Authors:  A Smits; E Westerberg; D Ribom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-21       Impact factor: 9.236

6.  Pitfalls in the assessment of disability in individuals with low-grade gliomas.

Authors:  Anneli Påhlson; Lena Ek; Gerd Ahlström; Anja Smits
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

Review 7.  Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.

Authors:  Trent R Hummel; Lionel M Chow; Maryam Fouladi; David Franz
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

8.  Stereotactic iodine-125 brachytherapy for the treatment of WHO grades II and III gliomas located in the central sulcus region.

Authors:  Maximilian I Ruge; Philipp Kickingereder; Stefan Grau; Franziska Dorn; Norbert Galldiks; Harald Treuer; Volker Sturm
Journal:  Neuro Oncol       Date:  2013-09-17       Impact factor: 12.300

9.  Patterns of care and treatment outcomes in older adults with low grade glioma: a 50-year experience.

Authors:  Ryan S Youland; David A Schomas; Paul D Brown; Ian F Parney; Nadia N I Laack
Journal:  J Neurooncol       Date:  2017-04-21       Impact factor: 4.130

Review 10.  Initial management of childhood brain tumors: neurosurgical considerations.

Authors:  Farideh Nejat; Mostafa El Khashab; James T Rutka
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.